Education
About Us
Working with TipRanks
Follow Us
Aspen Pharmacare (APNHY)
OTHER OTC:APNHY
APNHY Stock Chart & Stats
$6.80
$0.00(0.00%)
At close: 4:00 PM EST
$6.80
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.24 - $10.05
Previous CloseN/A
Volume14.00
Average Volume (3M)710.00
Market Cap
$3.43B
Enterprise Value$85.54B
Total Cash (Recent Filing)$6.41B
Total Debt (Recent Filing)$36.12B
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)-0.42
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume710
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.63
Price to Sales (P/S)1.23
P/FCF Ratio512.59
Enterprise Value/Market Cap24.93
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda31.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Pharma Scale & GrowthA dominant Commercial Pharma division delivering double-digit constant-currency revenue and EBITDA growth provides durable revenue concentration in higher-margin branded offerings. This scale and momentum supports pricing power, distribution leverage across emerging markets and steadier cash generation over coming quarters.
Balance Sheet ResilienceA strong equity ratio and moderate leverage give Aspen financial flexibility to absorb shocks, fund restructuring or investment, and reduce refinancing risk. This capital structure supports medium-term execution of turnaround initiatives without immediate reliance on aggressive external funding.
High Operating Cash ConversionReported operating cash conversion of 147% indicates capacity to convert accounting earnings into cash when sustained. Robust conversion supports deleveraging, targeted capex and working-capital resilience, improving the company's ability to self-fund strategic priorities over the next 2-6 months.
Bears Say
Free Cash Flow CollapseA 96% collapse in free cash flow sharply weakens liquidity and limits capacity to invest, service debt or return capital. Persistently depressed FCF undermines execution of strategic plans, increases refinancing risk and constrains the company's ability to fund recovery initiatives sustainably.
Loss Of Material ContractThe unexpected loss of a material contract that reduced EBITDA by ZAR 2bn highlights concentration and contract renewal risk. This hit lowers manufacturing utilization and long-run margin stability until replacement volumes or new contracts are secured, pressuring profitability trends.
Large Impairments And Tax HeadwindsSignificant intangible impairments and retroactive global tax regime changes materially reduce carrying values and raise effective tax rates. These structural hits lower future earnings power, increase earnings volatility and constrain the company's ability to generate sustainable returns on past acquisitions.
Aspen Pharmacare News
APNHY FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was $5.24 and its highest was $10.05 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is $3.43B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Mar 03, 2026 which is in 9 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Sep 03, 2025. The company reported -$0.425 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.425.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Overvalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare pays a Annually dividend of $0.122 which represents an annual dividend yield of 2.15%. See more information on Aspen Pharmacare dividends here
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of -$0.425 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.217%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in APNHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aspen Pharmacare Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.29%
12-Months-Change
Fundamentals
Return on Equity
-1.18%
Trailing 12-Months
Asset Growth
0.34%
Trailing 12-Months
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---